[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655595":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":37,"interventions":48,"overallOfficials":25,"centralContacts":56,"locations":25,"responsibleParty":62,"collaborators":25,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":25,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":93,"whyStopped":25,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":25},{"fullName":5,"class":6},"Ollin Biosciences, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"Change in BCVA","Change in ETDRS BCVA eye chart letter score from Day 1 to Week 48.","Day 1 to Week 48",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"Mean change in OCT CST","Difference in the mean change from baseline in OCT CST in the Study Eye between the OLN324 arm and the aflibercept arm","Day 1 to Week 16",{"measure":19,"description":20,"timeFrame":17},"Change in PED thickness","Difference in the mean change from baseline in PED thickness on OCT in the Study Eye between the OLN324 arm and the aflibercept arm",{"measure":22,"description":23,"timeFrame":24},"Percentage of participants without retinal fluid in the central subfield at Week 16","Difference in the percentage of participants with absence of both IRF and SRF in the central subfield of the Study Eye between the OLN324 arm and the aflibercept arm","Week 16",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":25,"whoMasked":32},"QUADRUPLE",[33,34,35,36],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[38,43],{"label":39,"type":40,"description":25,"interventionNames":41},"OLN324","EXPERIMENTAL",[42],"Drug: OLN324",{"label":44,"type":45,"description":25,"interventionNames":46},"Aflibercept","ACTIVE_COMPARATOR",[47],"Drug: Aflibercept",[49,53],{"type":50,"name":39,"description":51,"armGroupLabels":52,"otherNames":25},"DRUG","OLN324 by intravitreal injection at protocol-specified dosing intervals",[39],{"type":50,"name":44,"description":54,"armGroupLabels":55,"otherNames":25},"Aflibercept by intravitreal injection at protocol-specified dosing intervals",[44],[57],{"name":58,"role":59,"phone":60,"phoneExt":25,"email":61},"Varun Malhotra, MD","CONTACT","737-330-1517","ollinclinops@ollin.bio",{"type":63,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100655595","phase-3-phase-3-study-of-intravitreal-oln324-in-adults-with-neovascular-wet-age-related-macular-degeneration-namd-oln324-cp-04-100655595",false,"NCT07816315","Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)","A Phase 3, Randomized, Double-masked, Multicenter, Active Comparator-controlled Trial to Investigate the Efficacy and Safety of Intravitreal OLN324 in Adult Participants With Neovascular (Wet) Age-related Macular Degeneration (nAMD)","MOJAVE","Inclusion Criteria:\n\n* Capable of giving signed informed consent\n* Be ≥50 years of age\n* Treatment-naive nAMD in the study eye with active subfoveal choroidal neovascularization (CNV)\n* Have a decrease in vision in the study eye due to nAMD, with best corrected visual acuity of 78 to 24 letters\n* Additional inclusion criteria apply\n\nExclusion Criteria:\n\n* Be pregnant or breastfeeding\n* History of cataract surgery in the study eye within 90 days of Screening\n* Has uncontrolled glaucoma in the study eye\n* Has uncontrolled hypertension\n* Has had a stroke or myocardial infarction within 180 days\n* Additional exclusion criteria apply","ALL","50 Years",{"count":75,"type":76},500,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).",[82],"Wet Age Related Macular Degeneration",[84,5,85,86,87,88,89,90,91,39,92],"Ollin","nAMD","AMD","wet AMD","Neovascular AMD","Age-related macular degeneration","Wet age-related macular degeneration","Neovascular age-related macular degeneration","wAMD","NOT_YET_RECRUITING","2026-09-07",{"date":96,"type":97},"2026-09-11","ACTUAL",{"date":99,"type":76},"2026-10-15",{"date":101,"type":76},"2029-12-15",{"name":5,"class":6}]